Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT06155422 für Rezidivierender oder Metastasierender Gebärmutterhalskrebs ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer 670 Real-World-Daten
Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study
- AK104-RWS-002
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Cadonilimab-treated Recurrent or Metastatic Cervical Cancer | Cadonilimab recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Objective response rate (ORR) | ORR is proportion of subjects with complete response(CR) or partial response(PR), based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1 | from the first drug administration up to two years |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Disease control rate (DCR) | Disease control rate (DCR) is defined as the proportion of subjects achieving a best of response(BOR) of confirmed CR and PR and stable disease(SD) per RECIST v1.1. | from the first drug administration up to two years |
progression-free survival (PFS) | Progression-free survival (PFS) is defined as the time from the first dose of investigational products until documentation of PD (as per RECIST v1.1) or death due to any cause, whichever occurs first. | from the first drug administration up to two years |
overall survival (OS) | Overall survival (OS) is defined as the time from the first dose of investigational products until death due to any cause. | from the first drug administration up to two years |
Incidence and severity of adverse events(AEs) | Incidence and severity of AEs is aim to evaluate the safety of Cadonilimab in combination with other treatments. | from the first drug administration up to two years |
- The subject must sign the written informed consent form (ICF) voluntarily.
- Aged ≥ 18years, female.
- Histologically or cytologically confirmed cervical cancer, ① recurrent or metastatic (FIGO IVB) cervical cancer, not amenable to curative surgery or concurrent chemoradiotherapy, no prior systemic therapy for persistent, recurrent or metastatic disease, or ② subjects have demonstrated radiologically confirmed disease progression during or after last treatment, subjects will have no more than 2 lines of systemic therapy in the recurrence or metastatic stages. neoadjuvant chemotherapy, adjuvant chemotherapy, or Chemotherapy of non-recurrent or metastatic stage chemoradiotherapy,will not be counted as a treatment line number.
- The histological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.
- At least 1 measurable lesion per RECIST v1.1, which is applicable for repeated accurate measurement.
- Life expectancy> 12 weeks.
- Adequate organ function.
- Female patients with fertility must have a urine or serum pregnancy test within 3 days before the first medication (if the urine pregnancy test result cannot be confirmed as negative, a serum pregnancy test is required, based on the serum pregnancy result), and the result is negative. If a fertile female patient has sex with an unsterilized male partner, the patient must use an acceptable contraceptive method since screening and must consent to continued use of the contraceptive method for 120 days after the last administration of the study drug; Whether to stop contraception after this time point should be discussed with the investigator
- Subjects must be willing and able to comply with the scheduled visits, treatment regimens, laboratory tests, and other requirements in the study.
Subjects had clinically significant hydronephrosis that could not be relieved by nephrostomy or urethral stenting, as determined by the investigator.
Other active malignancies within 2 years prior to the first administration. Subjects with locally curable tumors that appear to be cured, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the breast, were not excluded.
Have received other study drugs or study devices within 4 weeks prior to the first administration.
Concurrent enrollment in another clinical study, unless it is an observational, non-interventional clinical study or a follow-up period of an interventional study. (It was defined as more than 4 weeks between the first administration of the drug in the study and the last administration of the drug in the previous clinical study or more than 5 half-lives of the drug in the study)
An active infection requiring systemic therapy.
Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 1000 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA <1000 IU/ mL), and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.
Known history of active tuberculosis (TB),In patients suspected of having active tuberculosis, chest x-rays, sputum, and clinical signs and symptoms should be examined for exclusion.
Receipt of live or attenuated vaccination within 30 days prior to the first administration, or plan to receive live or attenuated vaccine during the study.
There are any of the following cardiovascular and cerebrovascular diseases or risk factors for cardiovascular and cerebrovascular diseases:
Myocardial infarction, unstable angina pectoris, pulmonary embolism, acute/persistent myocardial ischemia, cerebrovascular accident, transient ischemic attack, or other arteriovenous thrombosis, embolism, or ischemic events that are clinically significant or require pharmacological intervention occurred within 6 months prior to initial administration.
Symptomatic congestive heart failure (classified as 3 or 4 according to the New York Heart Association functional classification) occurring within 6 months before the first administration.
Unstable arrhythmias or degree II/III atrioventricular blocks requiring pharmacological intervention occurred within 6 months prior to initial administration.
Known history of serious hypersensitivity reaction to other monoclonal antibodies.
Pregnant or lactating women.
Any condition that the investigator believes may result in a risk of receiving the study drug or combination therapy, or that would interfere with the evaluation of the study drug or with patient safety or analysis of the study results.
Gang Chen (101199)